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Abstract
Objective:  To  identify  the  occurrence  of  anemia  in  pediatric  patients  on  hemodialysis  and  the
association  between  hemoglobin  levels  and  anemia  in  CKD-related  variables.
Methods: This  was  a  retrospective  study.  Patients  aged  up  to  18  years  with  chronic  kidney
disease undergoing  hemodialysis  at  this  service  between  January  of  2009  and  December  of  2010
were  selected.  Clinical  and  laboratory  data  were  obtained  from  medical  records.  Statistical
analysis  was  performed  with  chi-squared  test,  Student’s  t-test  and  general  estimating  equations
(GEE)  using  SPSS  20.0,  assuming  a  signiﬁcance  level  of  5%.
Results:  A  total  of  357  medical  records  depicting  the  monthly  evolution  of  29  patients  were
analyzed. The  most  common  etiology  for  chronic  kidney  disease  was  malformations  of  the  geni-
tourinary  tract  (28%).  Hemoglobin  showed  a  mean  (standard  deviation)  value  of  9.20  (1.8)  g/dL,
with  the  occurrence  of  anemia  in  65.3%  of  cases.  Anemia  was  associated  with  hospitalization;
antibiotic use;  transfusion;  use  of  intravenous  iron  hydroxide;  low  values  of  creatinine,  hema-
tocrit,  and  albumin;  and  high  values  of  ferritin,  aluminum,  and  equilibrated  Kt/V  (p  <  0.05).
The  odds  ratio  for  anemia  with  the  use  of  intravenous  iron  hydroxide  was  0.36  (95%  CI:  0.25  to
0.89),  i.e.,  a  2.78-fold  higher  chance  of  developing  anemia  without  the  use  of  this  medication.
Conclusions:  Anemia  predominated  in  children  and  adolescents  with  chronic  kidney  disease;
intravenous iron  hydroxide  use  was  a  protective  factor.
©  2014  Sociedade  Brasileira  de  Pediatria.  Published  by  Elsevier  Editora  Ltda.  
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Avaliac¸ão  de  variáveis  clínicas  e  laboratoriais  associadas  à  anemia  em  pacientes
pediátricos  em  hemodiálise
Resumo
Objetivo:  Identiﬁcar  a  ocorrência  de  anemia  entre  pacientes  pediátricos  em  hemodiálise  e  a
associac¸ão  entre  os  valores  de  hemoglobina  e  variáveis  relacionadas  à  anemia  na  DRC.
Métodos:  Estudo  retrospectivo.  Selecionados  pacientes  até  18  anos  de  idade  com  doenc¸a renal
crônica em  hemodiálise  no  servic¸o entre  janeiro  de  2009  a  dezembro  de  2010.  Veriﬁcados
prontuários para  coleta  de  dados  clínicos  e  laboratoriais.  Análise  estatística  com  testes  de  qui-
quadrado,  t  de  Student  e  General  Estimating  Equations  (GEE)  em  programa  Statistical  Package
for  the  Social  Sciences  20.0,  assumindo-se  nível  de  signiﬁcância  de  5%.
Resultados: Analisadas  357  ﬁchas  de  evoluc¸ão  médica  mensal  de  29  pacientes.  A  etiologia  mais
frequente para  a  doenc¸a renal  crônica  foram  as  malformac¸ões  do  trato  genito-urinário  (28%).
Hemoglobina  apresentou  valor  médio  (desvio  padrão)  de  9,20  (1,8)  g/dL,  com  ocorrência  de
anemia  em  65,3%  das  consultas.  Anemia  associou-se  a  internac¸ão,  uso  de  antibiótico,  transfusão,
uso  de  hidróxido  de  ferro  endovenoso,  valores  baixos  de  creatinina,  hematócrito  e  albumina  e
valores  altos  de  ferritina,  alumínio  e  Kt/V  equilibrado  (p  <  0,05).  A  odds  ratio  para  anemia  com
uso  de  hidróxido  de  ferro  endovenoso  foi  0,36  (95%  IC  0,25-0,89),  ou  seja,  uma  chance  2,78
vezes  maior  de  desenvolver  anemia  sem  o  uso  dessa  medicac¸ão.
Conclusões:  A  anemia  predominou  em  crianc¸as  e  adolescentes  com  doenc¸a renal  crônica,  tendo
como fator  protetor  o  uso  de  hidróxido  de  ferro  endovenoso.
©  2014  Sociedade  Brasileira  de  Pediatria.  Publicado  por  Elsevier  Editora  Ltda.  
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he  prevalence  of  renal  replacement  therapy  in  children
ged 0-19  years  in  Brazil  is  of  23:1,000,000  in  the  related
ge range.  The  survival  of  these  children  is  approximately
0-fold lower  than  that  of  their  healthy  peers.  The  main
ause of  mortality  in  this  group  is  cardiovascular  disease,
ccounting for  40%  of  deaths,  and  anemia  is  identiﬁed  as  a
actor related  to  higher  rates  of  mortality.1,2
The  prevalence  of  anemia  in  Brazilian  children  without
 diagnosis  of  any  disease  ranges  from  25.6%  to  63.7%,3,4
hile  in  children  with  chronic  kidney  disease  (CKD),  chronic
yporegenerative anemia  is  common.  If  untreated,  it  can
ead to  growth  and  development  impairment,  left  ventri-
ular hypertrophy,  and  tachycardia.  When  on  hemodialysis,
lood loss  in  the  dialysis  circuit  and  blood  collections  due  to
requent examinations  contribute  to  further  exacerbation  of
nemia.5
Anemia  is  a  limiting  survival  factor  of  children  on
emodialysis. Thus,  this  study  aimed  to  identify  the  occur-
ence of  anemia  in  pediatric  patients  on  hemodialysis  and
he association  between  hemoglobin  levels  and  anemia-
elated variables  in  CKD.
ethods
tudy  design  and  settinghis  was  a  retrospective  cohort  study  approved  by  the  Ethics
ommittee in  Human  and  Animal  Medical  Research,  of  Hospi-
al das  Clínicas  da  Universidade  Federal  de  Goiás  (HC/UFG).
B
a
h
rata  were  collected  at  the  Renal  Replacement  Therapy
ervice, Hemodialysis  Sector,  HC/UFG.
tudy  participants
he  study  participants  were  subjects  undergoing  hemodial-
sis in  HC/UFG  between  January  of  2009  and  December
f 2010  who  met  the  inclusion  criteria:  age  < 18  years  and
iagnosis of  CKD.  Cases  whose  medical  records  were  not
vailable were  excluded.
ata  collection  and  variables
n  expert  researcher  (a  pediatric  nephrologist)  collected
he data  on  the  variables  of  interest  from  patients’  records,
peciﬁcally the  records  of  monthly  medical  progress,  and
ecorded them  in  digital  form.  Record  survey  was  conducted
t the  Hemodialysis  Sector  and  the  Division  of  Medical
ecords and  Health  Information  of  HC/UFG.
The  dependent  variable  was  the  occurrence  of  anemia,
easured by  hemoglobin  levels  (mg/dL).
The  independent  variables  were:  clinical  variables  -  hos-
italizations, antibiotic  use  in  the  month  (whether  the
atient used  or  not),  transfusions  of  packed  red  blood
ells, and  main  drugs  used  to  treat  anemia  (folic  acid,  B
omplex, vitamin  C,  erythropoietin,  and  intravenous  iron
ydroxide); laboratory  variables  - serum  tests  performed  as
outine at  the  service,  deﬁned  by  Resolution  No.  154  of  the
razilian National  Health  Surveillance  Agency,  with  relevant
djustments: urea  at  pre-hemodialysis  session,  creatinine,
emoglobin, hematocrit,  pH,  bicarbonate,  ferritin,  transfer-
in saturation  index  (TSI),  iron,  parathyroid  hormone  (PTH),
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cChildren  on  hemodialysis:  anemia  
albumin,  and  aluminum.6 Equilibrated  Kt/V  (EKT/V)  was  cal-
culated as  proposed  by  Fischbach  et  al.7
Statistical  Analysis
Data  were  tabulated  and  analyzed  using  descriptive  and
inferential statistics  using  IBM  SPSS  Statistics  software,
release 20  (IBM  Corporation,  NY,  USA).
After  exploratory  data  analysis,  continuous  variables
were categorized  based  on  clinical  parameters  to  better
interpret the  results,  considering  the  limited  number  of  sub-
jects included  in  the  study.
Serum  hemoglobin  values  were  classiﬁed  as  adequate  or
inadequate (anemia)  as  recommended  by  the  National  Insti-
tute for  Health  and  Clinical  Excellence  (NICE)  criteria  of
2011,8 which  considers  both  age  groups  (0-2  years  and  over  2
years). Student’s  t-test  and  the  chi-squared  test  were  then
used to  test  associations  between  the  described  variables
and the  occurrence  of  anemia.
This  longitudinal  observational  study  included  repeated
measurements for  the  same  variable  in  the  same  subject.  As
the dependent  variable  was  categorical  (having  or  not  ane-
mia), the  analysis  of  variance  for  repeated  measures  could
not be  used.  Moreover,  multiple  linear  regression  would  be
contraindicated because  the  assumption  of  independence
of random  variables  could  not  be  met,  as  the  data  had  an
interdependent association  (repeated  measures).  Thus,  the
statistical analysis  that  would  better  determine  predictive
variables for  anemia  were  the  generalized  estimating  equa-
tions (GEEs).9
The  GEE  approach,  which  is  an  extension  of  generalized
linear models,  was  developed  to  produce  more  efﬁcient
and less  biased  regression  estimates  for  use  with  cor-
related data,  as  repeated  longitudinal  measures.10 Thus,
GEE analyzes  data  depending  on  exposure  over  successive
periods of  time.  For  the  analysis  of  this  study,  a  model  for
the dependent  variable  ‘‘anemia’’  was  created.  The  inde-
pendent variables  were  ‘‘hospitalization’’,  ‘‘infection  of
double-lumen catheter  (DLC)’’,  ‘‘antibiotic  use,’’  ‘‘use  of
t
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neurogenic bladder
Association of GUT malformation
+ neurogenic bladder
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ARPKD
Sequelae of acute injury (HUS/sepsis)
Urinary metabolic disorder
(nephrocalcinosis/hyperoxalosis)
 Undetermined
Figure  1  Etiology  of  chronic  kidney  disease.
HUS, hemolytic  uremic  syndrome;  ARPKD,  autosomal  recessive  polyc
rosis;  GUT,  genitourinary  tract.
Total  =  100%.89
ntravenous  iron  hydroxide.’’  Missing  data  were  treated  by
he GEE  mechanism  that  uses  all  available  data  to  include
vasion data.  The  odds  ratio  (OR)  and  conﬁdence  intervals
95% CI)  were  calculated  to  reﬂect  the  possible  associations
etween predictive  factors  and  dependent  variable.
All  statistical  tests  were  two-tailed,  with  a  signiﬁcance
evel of  0.05.
esults
 total  of  31  patients  were  included,  but  two  were  excluded
ue to  inaccessible  ﬁles.  The  ﬁnal  sample  consisted  of  29
atients, corresponding  to  357  ﬁles  of  monthly  clinical  evo-
ution throughout  24  months.  Each  patient  was  followed-up
or one  to  23  consultations.  The  mean  age  of  patients  at
aseline was  10  years  and  3  months  (standard  deviation
SD] 34.6  months).  Of  the  29  patients  included,  21  were
ales (72.4%).  The  etiologies  of  CKD  with  their  respective
ercentages are  shown  in  Fig.  1.
All  patients  but  one  had  anemia  at  some  point  during
heir follow-up,  which  corresponded  to  65.3%  of  consul-
ations (n  =  233).  The  mean  hemoglobin  (g/dL)  for  the
ategorized groups  were:  anemic  -  8.2  g/dL  (SD  1.2);
on-anemic -  11.2  g  /  dL  (SD  1.0)  (p  <  0.001).  The  mean
emoglobin value  for  the  total  sample  was  9.2  (SD  1.8).
The  bivariate  analysis  showed  that  anemia  was  associated
ith several  clinical  situations  (Table  1):  need  for  hospital-
zation, antibiotic  use,  transfusion,  and  less  frequent  use  of
ntravenous iron  hydroxide  (p  <  0.05).  As  for  the  laboratory
ndings, anemia  was  related  to  lower  levels  of  creatinine,
ematocrit, and  albumin,  as  well  as  to  higher  values  of  fer-
itin and  aluminum,  and  EKt/V  (Table  1).
Based  on  the  results  of  the  chi-squared  and  Student’s
-test, the  authors  sought  to  determine  the  predictive  clini-
al factors  for  anemia  in  this  group  of  patients,  considering
he clinical  variables  that  reached  p  <  0.2  in  the  bivariate
nalysis. Among  these,  the  variable  ‘‘need  for  transfusion’’
as excluded,  as  it  is  not  logical  to  evaluate  this  vari-
ble as  a  predictor  of  anemia.  Thus,  through  GEE,  it  was
28%
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ystic  kidney  disease;  FSGS,  focal  and  segmental  glomeruloscle-
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Table  1  Association  between  clinical  and  laboratory  variables  and  the  occurrence  of  anemia  in  children  with  chronic  kidney
disease  on  hemodialysis  (357  ﬁles  of  29  patients).
Independent  variables n  Total  sample Anemia  p
Yes  (n  =  233)  No  (n  =  124)
Medical  history,  n  (%)
Need for  hospitalization  316  52  (14.6%)  43  (20.7%)  9  (8.3%)  0.005a
Antibiotic  use  316  60  (16.8%)  48  (23.1%)  12  (11.1%)  0.010a
Need  for  transfusion  316  11  (3.1%)  56  (26.9%)  3  (2.8%)  <  0.001a
Double-lumen  catheter  infection  316  59  (16.5%)  10  (4.8%)  1  (0.9%)  0.105a
Main  medications  used  in  the  treatment  of  anemia,  n  (%)
Folic  acid 339  333  (93.3%)  222  (98.7%)  111  (97.4%)  0.392a
Vitamin  B  complex 339  332  (93.0%) 221  (98.2%) 111  (97.4%)  0.601a
Vitamin  C  339  327  (91.6%)  219  (97.3%)  108  (94.7%)  0.222a
Erythropoietin  321  303  (84.9%)  201  (94.4%)  102  (94.4%)  0.977a
Intravenous  iron  hydroxide  318  160  (44.8%)  89  (42.4%)  71  (65.7%)  <  0.001a
Laboratory  exams,  mean  (standard  deviation)
Pre-hemodialysis  session  urea  (mg/dL)  353  140.5  (42.3)  143.2  (42.9)  135.5  (40.8)  0.104b
Creatinine  (mg/dL)  352  6.2  (2.1)  5.9  (2.1)  6.6  (2.1)  0.002b
Hematocrit  (%)  356  28.3  (5.7)  25.1  (4.0)  34.3  (3.0)  <  0.001b
Power  of  hydrogen  (pH)  (AV)  119  7.4  (0.6)  7.4  (0.1)  7.4  (0.1)  0.177b
Bicarbonate  (mmol/L)  120  20.2  (3.8)  19.8  (3.4)  20.7  (4.1)  0.197b
Ferritin  (ng/L)  351  709.3  (460.0)  754.0  (479.1)  625.1  (413.1)  0.012b
Transferrin  saturation  index  (TSI)  (%)  357  35.5  (19.4)  36.0  (20.2)  34.5  (17.9)  0.474b
Iron  (uG/dL)  340  75.7  (93.5)  74.7  (95.9)  78.0  (89.8)  0.754b
Parathormone  (PTH)  (pg/mL)  347  520.3  (495.1)  526.2  (519.4)  513.2  (450.7)  0.815b
Albumin  (g/dL)  343  3.9  (0.5)  3.8  (0.6)  4.1  (0.2)  <  0.001b
Aluminum  (ug/dL)  167  24.1  (28.6)  28.0  (30.8)  16.0  (21.6)  0.011b
Equilibrated  Kt/V  (eKt/V)  (AV)  294  1.9  (0.4)  2.0  (0.4)  1.8  (0.4)  0.004b
Values in bold show statistically signiﬁcant associations (p < 0.05).
AV,  absolute value.
a Pearson’s chi-squared test.
b Student’s t-test.
Table  2  Clinical  factors  predictive  of  anemia  in  children  and  adolescents  on  hemodialysis.
Independent  variables Odds  ratio 95% Conﬁdence  interval p  value
Minimum  Maximum
Need  for  hospitalization  1.00  0.52  1.93  0.988
Antibiotic  use  1.97  0.89  4.35  0.095
Double-lumen  catheter  infection  4.13  0.49  34.60  0.191
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pUse  of  intravenous  iron  hydroxide  0.36  
emonstrated  that  the  use  of  intravenous  iron  hydroxide
as a  protective  factor  for  anemia  (Table  2):  the  odds  the
hildren on  hemodialysis  to  have  anemia  when  using  this
edication was  0.36  times  the  odds  of  those  who  did  not
se it.  Calculating  the  inverse  of  0.36,  it  is  observed  that  the
hance of  children  who  did  not  use  intravenous  iron  hydrox-
de to  have  anemia  was  2.78  times  the  chance  of  those  who
sed it.  The  other  variables  did  not  show  such  signiﬁcant
redictors in  the  GEE.iscussion
his  article  emphasizes  the  high  prevalence  of  ane-
ia in  children  undergoing  hemodialysis,  in  spite  of  the
l
d
n
c0.25  0.89  <  0.001
dministration  of  recombinant  human  erythropoietin,  and
eafﬁrms the  importance  of  intravenous  iron  supplemen-
ation in  this  population.
In relation  to  the  clinical  aspects  of  this  study,  it
s noteworthy  that,  among  the  causes  of  CKD,  congen-
tal malformations  of  the  urinary  tract  were  the  most
revalent, consistent  with  data  obtained  in  developed
nd developing  countries.  However,  neurogenic  bladder
as the  second  most  prevalent  cause  observed  in  the
resent study  and  by  researchers  in  Turkey,  while  glomeru-
onephritis and  hereditary  nephropathies  were  observed  in
eveloped countries.  This  may  reﬂect  a delay  in  the  diag-
osis and  treatment  of  urological  problems  in  developing
ountries.1,11--13
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It  is  worth  mentioning  the  use  of  medications  for  the
treatment of  CKD-associated  anemia:  94.4%  used  erythro-
poietin; 50.5%  used  intravenous  iron  hydroxide  in  the
present study.  In  the  Brazilian  dialysis  census  of  2011,
prescriptions of  these  medications  were  80.0%  and  53.1%,
respectively.14
The  target-hemoglobin  values  for  children  and  adoles-
cents with  CKD  in  the  literature  are  divergent  and  have
been revised  over  the  past  years.12,15,16 It  is  known  that,
in children  and  adolescents,  age  and  gender  should  be
taken into  account  in  order  to  deﬁne  target  hemoglobin
(Hgb) values.17 The  recommendation  of  the  last  NICE
criteria8 to  deﬁne  Hgb  in  patients  as  adequate  or  inade-
quate was  adopted;  therefore,  the  present  study  showed
that Hgb  values  below  the  expected  (anemia)  were  found
in most  monthly  records  of  patients  (65.3%),  albeit  still
above those  found  in  the  last  Brazilian  dialysis  census
(39.3%).14
The  authors  believe  that  this  difference  is  due  to  the
study methodology,  in  which  the  same  patient  with  ane-
mia was  reviewed  during  successive  months,  overestimating
the frequency  of  anemia.  In  other  studies,  the  hemoglobin
value is  usually  considered  in  a  single  annual  measurement
(only one  month  of  the  year);  the  authors  believe  that  this,
conversely, may  underestimate  the  prevalence  of  anemia.
The mean  Hgb  observed  was  9.2  (SD  1.8)  g/dL.  Compar-
atively, American  data  show  a  mean  Hgb  of  11.5  (SD  1.6)
g/dL, with  68%  of  patients  showing  the  target  Hgb  values.2
Data  from  the  United  Kingdom  showed  that  most  children
on renal  replacement  therapy  are  anemic  (47%  of  children
on hemodialysis).18 A  Polish  study  evidenced  a  mean  Hgb  of
10.91 (SD  1.2)  g/dL.19
It  is  known  that  serum  Hgb  varies  over  the  months,  and
withdrawal of  erythropoietin  in  the  last  60  days  and  hos-
pitalization are  related  to  Hgb  <  11  g/dL.  The  longer  the
hospital length  of  stay,  the  greater  the  chance  of  more
signiﬁcant decreases  in  Hgb  values.20 A  14.6%  rate  of  hos-
pitalization was  observed  in  the  present  study,  which  may
also have  contributed  to  the  anemia  in  the  present  popu-
lation. Appropriate  values  of  serum  albumin  are  related  to
adequate Hgb  values.21 Adequate  mean  serum  albumin  lev-
els were  observed  in  the  present  study,  in  agreement  with
other authors.15,19
Good  markers  of  ferritin  and  transferrin  saturation
index (TSI)  were  identiﬁed,  as  the  iron  stores  are  replen-
ished intravenously,  as  recommended  in  the  literature  for
over a  decade  for  hemodialysis  patients  receiving  human
erythropoietin.22,23
In  91.6%  of  the  ﬁles,  patients  were  receiving  vitamin  C,
which is  important  for  release  of  iron  stored  in  the  body,
ensuring its  availability  for  erythropoiesis.24,25
When  the  GEE  was  performed,  intravenous  iron  hydroxide
received during  that  month  showed  to  be  protective  against
anemia. The  variable  ‘‘transfused’’  was  removed  from  the
GEE analysis,  as  it  ultimately  reﬂects  the  event  throughout
the month.  A  blood  sample  was  collected  for  the  monthly
tests on  the  ﬁrst  Thursday  of  each  month.  Those  who  met  the
criteria for  receiving  packed  red  blood  cells  (including  the
low Hg  values)  received  the  blood  product  in  subsequent  ses-
sions. Thus,  the  answer  ‘‘yes’’  to  the  variable  ‘‘transfused’’
meant that,  during  that  month,  hemoglobin  levels  were  very
low and  the  patient  required  blood  transfusion.  Therefore,
191
he  transfusion  event  could  be  erroneously  indicated  as  a
isk factor  for  anemia  in  the  GEE.
The  main  limitation  of  this  study  was  its  retrospective
esign, with  analysis  of  data  found  in  medical  records.  The
ack of  control  in  data  collection  and  information  loss  consti-
ute biases  of  retrospective  studies.  These  were  observed  in
he present  study,  compromising  the  sample  and  decreasing
he power  of  data  representation.  The  longitudinal  repeated
easures were  treated  by  GEE.
In  conclusion,  the  study  population  consisted  of  children
nd adolescents  with  end-stage  renal  disease  on  hemodial-
sis. Anemia  was  prevalent  and  the  use  of  intravenous  iron
ydroxide was  a  protective  factor.
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